Tempest Therapeutics, Inc. (TPST) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tempest Therapeutics, Inc. on August 13, 2026. The filing serves to announce the Company's financial results for the quarter ended June 30, 2026, and other business highlights. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing references "other business highlights" in the attached press release but does not detail specific guidance, outlook, management commentary, risks, contingencies, or unusual items within the text of this report. The information is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2026) for specific Q2 2026 financial figures.
- Verify the Company's cash runway and burn rate, as these are critical for a biopharmaceutical entity and are not listed in this summary.
- Confirm any updates to clinical trial timelines or regulatory milestones mentioned in the "business highlights."
- Check for any new debt covenants or liquidity events disclosed in the full press release.